Loading…

Structure–Activity Relationship for the Picolinamide Antibacterials that Selectively Target Clostridioides difficile

Clostridioides difficile is a leading health threat. This pathogen initiates intestinal infections during gut microbiota dysbiosis caused by oral administration of antibiotics. C. difficile is difficult to eradicate due to its ability to form spores, which are not susceptible to antibiotics. To addr...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2021-06, Vol.12 (6), p.991-995
Main Authors: Speri, Enrico, Qian, Yuanyuan, Janardhanan, Jeshina, Masitas, Cesar, Lastochkin, Elena, De Benedetti, Stefania, Wang, Man, Schroeder, Valerie A, Wolter, William R, Oliver, Allen G, Fisher, Jed F, Mobashery, Shahriar, Chang, Mayland
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clostridioides difficile is a leading health threat. This pathogen initiates intestinal infections during gut microbiota dysbiosis caused by oral administration of antibiotics. C. difficile is difficult to eradicate due to its ability to form spores, which are not susceptible to antibiotics. To address the urgent need for treating recurrent C. difficile infection, antibiotics that selectively target C. difficile over common gut microbiota are needed. We herein describe the class of picolinamide antibacterials which show potent and selective activity against C. difficile. The structure–activity relationship of 108 analogues of isonicotinamide 4, a compound that is equally active against methicillin-resistant Staphylococcus aureus and C. difficile, was investigated. Introduction of the picolinamide core as exemplified by analogue 87 resulted in exquisite potency and selectivity against C. difficile. The ability of the picolinamide class to selectively target C. difficile and to prevent gut dysbiosis holds promise for the treatment of recurrent C. difficile infection.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.1c00135